BioCardia Q2 net loss narrows to $1.6M; PMDA supports CardiAMP Japan filing

BioCardia, Inc.

Q2 2026 net loss $1.6M vs $2.0M year-ago; H1 loss $3.9M vs $4.8M.
R&D expense down to $0.9M from $1.4M; cash $4.1M, runway into 2027.
Raised ~$4.9M net proceeds from ATM facility in Q2.
Japan PMDA supports Shonin submission for CardiAMP; filing targeted Q4 2026.
FDA confirms CardiAMP HF II trial may support PMA; Helix DeNovo approval possible.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.